We focus on developing pioneering and novel peptide Bio-drugs in specialist therapeutic areas

ImmuPharma PLC is an AIM listed (LSE:IMM) evolving speciality pharma company headquartered in London with its research team, ImmuPharma Biotech, based in Bordeaux, France

Our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value and to work with many leading scientists and clinicians. ImmuPharma has exclusive rights to all its intellectual property assets.

Since a major Board and management restructuring, the team has refocused it key pipeline portfolio to maximise long-term shareholder value.

Our pipeline

The pipeline of innovative peptide-based therapies is focused on two core therapy areas: Autoimmunity & Inflammation and Anti-infection.

These include:

  • Lupuzor™ (P140) for Lupus (Ph 2/3 adaptive/pivotal)
  • P140 for CIDP (Ph 2/3 adaptive/pivotal)
  • BioAMB, a novel, improved amphotericin-B (late preclinical)
  • BioCIN, a novel, improved vancomycin (early preclinical)

Business development

Our commercial strategy is to out-license our assets in development at value inflection points, to leading international corporations that are well-placed to further develop and/or commercialise our drugs.

ImmuPharma and Avion Pharmaceuticals now have an exclusive licence and development agreement for Lupuzor™, where Avion Pharmaceuticals is funding a new international Phase 3 trial and commercialise in the US.

Why Invest in ImmuPharma?

  • A rich portfolio with 2 highly attractive late-stage clinical indications – Lupus & CIDP
  • Near-term business development opportunities across all programs
  • Innovative Bio-drug platform of P140 has potential in several autoimmune diseases

The story so far...